Genentech Meets With Eye Groups Protesting Avastin Sales Restrictions
Executive Summary
Eye doctors furious over Genentech's decision to halt sales of Avastin to compounding pharmacies have succeeded in grabbing the company's attention. On Oct. 26, three of Genentech's top officers, CEO Arthur Levinson, Chief Medical Officer Hal Barron, and president of product development, Susan Desmond-Hellmann, traveled to Washington, D.C. to meet with two physician groups
You may also be interested in...
Alcobra’s Pipeline In A Pill Aims To Capture The ADHD Market And More
Founded in 2008, Alcobra has ridden a wave of impressive data, a friendly reception on the public markets, and growing investor interest in its bid to capture the ADHD market. Now, as it nears the start of Phase III for metadoxine, its unrelenting focus is on execution.
End Of The Year Approvals And Actions, In Brief
Ferring plans prostate cancer drug launch: After securing FDA approval of degarelix for advanced prostate cancer, the Swiss pharma is planning a launch in the first quarter after finalizing the trade name with FDA. Degarelix is a gonadotropin releasing hormone receptor antagonist that suppresses testosterone, and could have an advantage over existing hormonal treatments like Abbott's Lupron Depot because it hasn't shown the initial surge in testosterone production that has been seen with some other agents, according to FDA. Testosterone plays an important role in the growth of prostate cancer, so suppressing testosterone can slow the growth and progression of prostate tumors. Degarelix was compared to leuprolide in the Phase III study supporting approval. For the U.S. launch, Ferring plans to expand its existing urology sales force from 85 reps to 115
End Of The Year Approvals And Actions, In Brief
Ferring plans prostate cancer drug launch: After securing FDA approval of degarelix for advanced prostate cancer, the Swiss pharma is planning a launch in the first quarter after finalizing the trade name with FDA. Degarelix is a gonadotropin releasing hormone receptor antagonist that suppresses testosterone, and could have an advantage over existing hormonal treatments like Abbott's Lupron Depot because it hasn't shown the initial surge in testosterone production that has been seen with some other agents, according to FDA. Testosterone plays an important role in the growth of prostate cancer, so suppressing testosterone can slow the growth and progression of prostate tumors. Degarelix was compared to leuprolide in the Phase III study supporting approval. For the U.S. launch, Ferring plans to expand its existing urology sales force from 85 reps to 115